Articles tagged with Blood Cancer
A new study by Dr. Thomas Walle found that resveratrol, a widely sold dietary supplement, is unlikely to have an effect on breast and prostate cancers when consumed in the diet or as a supplement. However, it may still prevent cancers along the aerodigestive tract, suggesting further research is needed.
Researchers developed a biomarker to detect HBV mutations that speed up liver cancer development. Studies found HBV mutations predicted major liver disease, including liver cancer, up to eight years before diagnosis.
Researchers discovered that BCR/ABL oncogene blocks normal DNA repair mechanism, leading to genetic mutations and blast crisis. This breakthrough may lead to long-term treatment for chronic myelogenous leukemia, a fatal blood cancer affecting people over 40.
Researchers at Dana-Farber Cancer Institute have discovered that the MLL gene is necessary for the development of master stem cells that generate all mature blood cells. The study suggests that MLL is part of a select set of genes required for all definitive blood lineages in the embryo.
A new study by St. Jude/Mayo Clinic researchers found a direct link between the CBP gene and lymphoma development in mice, with the loss of CBP promoting T-cell lymphoma and cooperating with reduced p27Kip1 protein levels. The study suggests that CBP plays a role in cancer development despite normal p53 activity.
Researchers explored the potential of copper to control cancerous growth by depleting it of essential nutrients. Studies have shown that regulating copper levels can stop tumor growth, although no cures have been found yet, and further research is needed for a more comprehensive approach.
A study published in The Journal of the American Medical Association found that people with higher CRP levels were more likely to develop colorectal cancers over an 11-year period. Median CRP levels were higher among those who developed colon cancer, and inflammation was linked to increased risk without being mediated by diabetes.
Case Western Reserve University scientists identified a protein called clusterin that can signal cell distress and detect cancer. A simple blood test could potentially identify abnormal clusterin levels, indicating the presence of cancer.
Researchers at the University of Iowa have discovered a way to improve cancer immunotherapy by directing specific types of white blood cells to kill cancer cells. By using CpG ODN agents, doctors can gear up natural killer cells and granulocytes to work with antibodies to target cancer cells more effectively.
Researchers found that patients with smoking-related cancers had shorter telomeres than those without cancer, and that short telomeres were associated with a greater cancer risk. Smoking status significantly influenced the effect of short telomeres on cancer risk.
A new treatment, interleukin-11 (IL-11), has shown early promise in reducing the risk of infection in patients undergoing chemotherapy for blood cancer. Patients who received IL-11 experienced significantly fewer cases of bacterial infections compared to those who received a placebo.
Researchers discovered that the Id1 gene regulates angiogenesis in melanoma, breast, head and neck, brain, cervical, prostate, pancreatic, and testicular cancers by reducing thrombospondin-1 production. This reduction leads to increased tumor blood vessel formation.
A comprehensive periodontal examination can save lives by detecting undiagnosed protein S deficiency, a condition that causes thrombotic disorders and increases the risk of strokes and heart attacks. Early diagnosis is key to successful treatment outcomes and improved survival rates for patients with this condition.
A new computer-based algorithm identifies a distinct proteomic pattern that distinguishes malignant from benign tumours within the ovary with 100% sensitivity and 95% specificity. This technique may help screen for ovarian cancer in high-risk and general populations.
A new combination of MabThera and standard chemotherapy has shown a significant increase in overall survival rate and complete remission rates in patients with aggressive non-Hodgkin's lymphoma. This treatment offers hope for improved outcomes in this increasingly common form of blood cancer.
Researchers at Fox Chase Cancer Center have discovered that the drug Oltipraz can inhibit tumor growth by blocking blood vessel formation, while also increasing protective detoxification enzymes in the body. This dual mechanism of action may make Oltipraz a promising agent for both cancer prevention and treatment.
Dr. Scott Cameron, a renowned pediatric oncologist and molecular biologist, will lead research on cell growth and cancer at UT Southwestern Medical Center. The Children's Cancer Fund provided a $525,000 grant to support his four-year research program.
A Swedish study published in The Lancet found no association between antihypertensive drug treatments and an increased risk of cancer. The study analyzed 6600 patients with hypertension, randomly assigning them to three treatment strategies, and found no significant difference in cancer incidence between groups.
A new DNA chip method has been developed to identify and classify tumor types, offering a promising approach for cancer diagnosis and treatment. The technique uses gene expression analysis to distinguish between different types of leukemia, such as AML and ALL, and may also be used to predict clinical outcomes.
Oregon Health & Science University scientists begin human trials of a targeted drug therapy for chronic myelogenous leukemia, aiming to eliminate leukemia cells with a faulty gene. The investigational drug has shown success in destroying BCR-ABL cells in mice and animal trials.
Cornell University researchers found that retinoic acid reverses the growth-promoting effects of oncogenes, which induce cancer. The study suggests enhanced therapies for leukemia and highlights the cancer-prevention role of carotenes in a diet rich in yellow-orange vegetables.
Researchers at Oak Ridge National Laboratory use ORNL mice to study human cancers, identifying genetic causes and potential treatments. By comparing mouse genes to human genes, scientists hope to gain a better understanding of cancer development and improve diagnosis and treatment strategies.
Researchers identify a molecular 'safety key' that normally regulates cell growth, and discovering how it can be disrupted to trigger cancer. The team found a protein called Abi-2 that fits into the normal enzyme cABL, keeping it turned off, and proposes a new way to treat cancers by targeting this molecular pathway.